Articles tagged with Multiple Sclerosis
A study found widespread damage to normal-appearing brain tissue in patients with multiple sclerosis, affecting large fractions of white and gray matter. This damage plays a larger role in disease progression than visible lesions.
A new study of twins found that genetic susceptibility to Multiple Sclerosis is significantly increased among those born in the northern environment, with a higher concordance rate among identical twins. Northern residence also contributed to an earlier onset of the disease, suggesting environmental factors play a crucial role.
A specific signal in cells in the nervous system aggravates MS symptoms, which could be alleviated by blocking related proteins. Blocking these proteins is promising as a strategy for new therapies against MS.
A new study found that men with multiple sclerosis (MS) are more likely to pass the disease to their children than women. The researchers discovered that fathers with MS have twice as many children who develop MS as mothers with the disease.
This article discusses various aspects of multiple sclerosis (MS) management in veterans, including the use of medical informatics, healthcare information systems, and patient education. The study highlights the importance of effective care models, registry development, and provider education to improve outcomes for MS patients.
Researchers found that eliminating a molecular switch allows immune cells to enter the central nervous system (CNS), leading to symptoms similar to multiple sclerosis. Eliminating this switch prevents destructive immune cells from entering CNS tissue, keeping mice healthy.
Research suggests that initiating MS therapy with an immunomodulating drug as soon as possible following a diagnosis can significantly reduce future disease activity and progression of disability. Studies have shown that delaying treatment is associated with more progression of disability and larger volumes of disease damage.
Researchers found that suppressing interferon-gamma can prevent damage to myelin-producing cells in the nervous system. Transgenic mice with SOCS1 gene showed reduced symptoms and cell loss compared to those without it.
Researchers found that T cells responding to Epstein-Barr virus-encoded nuclear antigen1 (EBNA1) are hyper-reactive and produce interferon-gamma, which shapes immune responses. This hyper-reactivity may trigger the destruction of myelin sheathing in nerve cells, leading to MS.
A new MS Research Centre will be established at the University of Edinburgh to develop therapies for Multiple Sclerosis using latest techniques and investigate repairing damaged nervous system parts. The centre aims to unlock MS mysteries and potentially lead to a cure, with £2.5m funding from JK Rowling and MS Society Scotland.
Researchers explore risk factors for dementia, including the Mediterranean diet and obesity, as well as novel treatments for Alzheimer's and multiple sclerosis. Experimental therapies also show promise in treating ALS and stroke, with potential applications in other neurodegenerative diseases.
A new clinical trial launched by Mount Sinai aims to determine whether a combination therapy is more effective than individual treatments in slowing or halting progression of Relapsing-Remitting Multiple Sclerosis. The study will recruit 1000 patients and assess the impact of treatment over 36 months.
Researchers found elevated antibodies to EBV in individuals with MS, persisting up to 20 years before symptoms. The study suggests a strong link between EBV and MS risk, but the exact mechanisms remain unclear.
Researchers found a significant association between Epstein-Barr virus infection and multiple sclerosis (MS), with elevated antibody levels before symptom onset. The study suggests Epstein-Barr virus may predispose individuals to autoimmunity, paving the way for new treatments and prevention strategies.
Cuba Gooding Jr. receives the award for his work raising awareness about multiple sclerosis, a condition affecting millions worldwide. The American Academy of Neurology recognizes his efforts to educate and support those living with MS.
Patients with relapsing forms of MS taking Betaseron experienced a sustained 40% reduction in annual relapse rates over 16 years. Long-term treatment showed slower disease progression, with those on therapy reaching EDSS 6.0 after a median time of 13 years.
A research team led by Bibiana Bielekova found that daclizumab increases the number of regulatory natural killer cells, which correlates with better treatment outcomes for MS patients. The study suggests that daclizumab may not damage the immune system but rather shifts its reaction from T-cells to natural killer cells.
A recent study published in the Journal of Clinical Investigation sheds light on the mechanism underlying microglia's behavior in multiple sclerosis. Researchers found that controlled inflammatory responses can restore damaged myelin and nerve function, suggesting a potential therapeutic target for MS treatment. Additionally, studies o...
Research findings clarify microglia's induction and blockage of oligodendrogenesis in MS, shedding light on disease mechanisms. The study highlights the complex interplay between microglial activation and oligodendrogenesis in MS.
Researchers found that combining immune modulating drugs can greatly reduce MS disease severity, with less myelin loss and CNS inflammation. The combination therapy utilized lower doses of each drug and promoted the secretion of anti-inflammatory molecules IL-10.
Researchers have found that combining Lipitor with Glatiramer acetate can prevent or diminish paralysis in mice with experimental autoimmune encephalomyelitis, a model disease closely resembling MS. The study demonstrates the potential of this combination therapy for treating central nervous system autoimmunity.
Researchers found combining atorvastatin with glatiramer acetate significantly improved treatment outcomes for multiple sclerosis. The study showed a synergistic effect between the two medications, leading to better control of CNS autoimmunity.
Researchers at Johns Hopkins Medicine have identified a new potential biomarker for multiple sclerosis, a protein fragment called 12.5 kDa cystatin found in cerebrospinal fluid, which may help diagnose the disease and monitor treatment efficacy.
Two Stanford University neurologists warn that clinical trials can be disastrous when a drug with unknown side effects is tested on healthy patients. They advocate for stricter entry criteria to prevent similar mistakes in the future.
A study conducted by the NIH and NINDS evaluated patients treated with natalizumab for relapsing-remitting MS and found no new cases of PML. However, the researchers caution that the long-term risk associated with natalizumab treatment is unknown.
Researchers at UT Southwestern Medical Center are exploring the potential of reparative cells to repair damage in multiple sclerosis. The study identifies specific injury cascades and molecular mechanisms that could be targeted for treatment, offering a new avenue for fighting this debilitating disease.
A new study found no new cases of progressive multifocal leukoencephalopathy (PML) and confirmed three previously identified cases associated with natalizumab use. The risk of contracting PML may be as low as one in 5,000 or as high as one in 300.
A study published in the Journal of Clinical Investigation found a connection between cataract development and cholesterol levels. Researchers discovered that rats with specific gene mutations had lower cholesterol levels in their eyes, suggesting an abnormality in epithelial cell maturation contributing to lens opacity. This link has ...
Researchers found that leptin blockade improved clinical symptoms of disease, slowed progression, reduced relapses, and reduced antigen-specific T cells in experimental autoimmune encephalomyelitis. Additionally, the study suggests that leptin neutralization may be a potential way to treat multiple sclerosis.
Research reveals that blocking the fat hormone leptin can slow disease progression and reduce symptoms in multiple sclerosis. Leptin blockade improves clinical symptoms, slows disease progression, reduces disease relapses, and decreases antigen-specific T cells.
Researchers found that anandamide, a brain's own cannabis compound, protects neurons from inflammation after damage. Adding AEA to damaged brain tissue abolished inflammatory damage, but not primary excitotoxic damage.
A study found that azathioprine, an immunosuppressive drug, effectively suppresses new brain lesions in relapse-remitting MS patients. The treatment showed remarkable and stable reduction of new brain lesions over a period of 12 months.
A pilot study on an online information system for multiple sclerosis patients will be conducted using the software developed by Cerner Corp., enabling direct access to medical records and prescription drugs, as well as private e-mail correspondence with physicians.
Researchers have identified two proteins found in the Neurofascin gene that link glial ensheathment of nerve fibers to node formation. This breakthrough discovery may help find ways to improve nerve conduction in patients with conditions like MS.
Neuroscientists at Thomas Jefferson University have found that glucosamine can significantly delay the onset of multiple sclerosis (MS) symptoms and improve movement in animal models. The anti-inflammatory effects of glucosamine may be useful in conjunction with existing treatments to help patients manage MS-related debilitating effects.
The new criteria allow for an earlier diagnosis of multiple sclerosis with minimal loss of diagnostic accuracy. The revised guidelines also reduce the number of MRI scans required to evaluate disease progression, making it a powerful tool for diagnosing MS and excluding alternative diagnoses.
A Stanford study finds that certain tryptophan metabolites can alleviate symptoms of multiple sclerosis, a condition affecting over 2.5 million people worldwide. The research suggests that diet and immunity are linked, with tryptophan playing a pivotal role in immune system regulation.
A new study at the University at Buffalo will explore the impact of cooling on exercise performance in people with multiple sclerosis (MS). The researchers aim to determine which cooling method is most effective and improve physical functioning and cardiovascular health.
A study found that patients with multiple sclerosis were more likely to carry a specific variation of the gene EBF-1, which is involved in axonal damage. The researchers also discovered that one version of the microsatellite within the gene was more frequently found in MS patients than healthy controls.
A study published in the Journal of Immunology suggests that the immune-cell substance MIF may be necessary for multiple sclerosis progression, but less important for initiating the disease. Researchers found that mice lacking MIF developed an acute phase of the disease, but then recovered without further signs of progression.
The Phase II study showed that FTY720 reduced annualized relapse rates by at least 50% during the first six months and maintained this rate for an additional six-month extension. Patients who switched to FTY720 after six months experienced a reduction of at least 70% in their annualized relapse rate compared to placebo.
Johns Hopkins researchers identify elevated levels of IL-6 in spinal fluid of patients with transverse myelitis, a condition that can lead to permanent paralysis. The study also found correlations between IL-6 levels and disease severity, shedding light on the mechanisms behind demyelinating disorders.
The study identifies aquaporin-4 as the target molecule of the NMO antibody, a significant finding that deviates from previous research on multiple sclerosis. The discovery may lead to the development of new therapies for neuromyelitis optica and other autoimmune disorders.
A definitive gene screen has confirmed the major histocompatibility complex genes' significant influence on multiple sclerosis (MS) genetics. The study, which analyzed genetic data from over 730 families, found critical implications for future MS research directions.
Researchers at Yale University have developed two ways to induce MS symptoms in mice, revealing a key distinction between disease-causing and non-disease antibodies. The study brings the team closer to pinpointing accurate diagnostic tools for individual MS patients.
A study of 1,001 women found that oral contraceptive users had a 40% lower incidence of multiple sclerosis compared to non-users. Pregnancy also showed a lower risk, while the postpartum period increased the risk of MS onset. Estrogen levels may play a role in these findings.
The study found that repeated administration of interferon beta-1b decreased the rate of new 'black hole' lesions but did not affect their duration. This suggests that the drug may be neuroprotective but does not change the underlying pathological process in multiple sclerosis.
A new study found that telephone-administered cognitive-behavioral therapy (T-CBT) significantly improved depression symptoms in patients with multiple sclerosis. The treatment was more effective than supportive emotion-focused therapy (T-SEFT) and showed lasting gains.
Research confirms that patients with inflammatory bowel disease (IBD) are more likely to develop conditions such as asthma, multiple sclerosis, and other demyelinating disorders. The studies found a nearly two-fold increased risk of multiple sclerosis in IBD patients, highlighting the need for closer monitoring.
Dr. Green will receive a $75,000 per year grant to study the inner retina and optic nerve in people with MS using optical coherence tomography. This research aims to predict disability in MS patients by observing early changes in the retina.
A large study found no link between MS risk and birth order position, contradicting the hygiene hypothesis. In fact, individuals with MS tended to be born later in larger sibships than expected.
The study suggests that different patterns of tissue damage in MS patients require different treatment approaches. Plasma exchange treatment was found to be most helpful for severe attacks in patients with pattern II MS lesions, which contain large quantities of immunoglobulins and complement activation.
Researchers at UW-Madison are developing cell transplant techniques to repair damaged myelin and protect nerve fibers in multiple sclerosis. The $3.4 million grant will support the use of human stem cells and minocycline, an antibiotic with anti-inflammatory properties.
Researchers have been awarded $15.6 million to develop tools for repairing nervous tissue damage in multiple sclerosis (MS), a promising step forward for this debilitating disease. The funds will support international collaborations of leading scientists and physicians working to protect against and repair MS-related nerve damage.
Researchers identify signal in damaged brain that prevents cells from restoring lost myelin; HA accumulation linked to CD44 protein. Oligodendrocyte progenitors can be prevented from maturing into myelin-producing cells, while injection of HA into damaged myelin prevents reforming.
Researchers have found a way to increase the potency of Khellinone, a naturally occurring substance with anti-inflammatory properties. By disrupting rogue T cell potassium channels, the compound reduces myelin damage and may help tackle multiple sclerosis.
Scientists found that interleukin-12 allows some immune cells to bypass normal regulation and cause damage to the myelin coating in nerve cells, contributing to MS symptoms. The discovery may lead to new treatments for MS by inhibiting IL12 and restoring the function of T-regulatory cells.
A study published in the Journal of Neuroscience Research found that patients with multiple sclerosis (MS) have lower expression of the FOXP3 gene, leading to reduced immune suppression. A new drug called NeuroVax was shown to increase FOXP3 levels and restore immune regulation in some patients.
Researchers found that bacterial infections trigger the production of antibodies against 'self' glycosphingolipids, leading to autoreactive T cell activation. This mechanism may contribute to the pathogenesis of autoimmune diseases such as multiple sclerosis and Guillain-Barré syndrome.
A recent OHSU study suggests that ginkgo biloba may improve attention in MS patients with cognitive impairment, with minimal side effects. The study found that patients taking ginkgo performed better on a test measuring attention and executive functions compared to those receiving a placebo.